Hillstar Bio is ushering in a new era in autoimmune disease treatment through precision immunology. The company selectively targets and depletes pathogenic immune cells while sparing healthy ones, offering the potential for durable relief and immune reset for patients with autoimmune conditions. Unlike traditional therapies that broadly suppress the immune system, Hillstar Bio's targeted approach addresses specific disease mechanisms by eliminating the underlying source and reducing the risks associated with chronic broad immunosuppression. =
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
03/25/25 | $67,000,000 | Series A |
DROIA Ventures Frazier Life Sciences Hummingbird Bioscience LifeArc Novo Holdings | undisclosed |